Stock Market & Financial Investment News

News Breaks February 14, 2013 07:13 EDT VSTM Verastem files for orphan disease status for VS-6063 in mesothelioma Verastem filed an orphan drug designation for VS-6063. Verastem is seeking orphan drug designation in the US and the EU for the use of VS-6063 in mesothelioma. VS-6063 is anticipated to enter a potentially pivotal study in mesothelioma midyear 2013. Orphan designation grants US market exclusivity to a drug for the treatment of a specified condition for a period of seven years following FDA marketing approval and 10 years of market exclusivity in member states of the EU if received. News For VSTM From The Last 14 Days Check below for free stories on VSTM the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. June 18, 2013 07:22 EDT VSTM Citigroup to host a conference Subscribe for More Information June 13, 2013 07:03 EDT VSTM Verastem gets European orphan designation for VS-6063 in mesothelioma Subscribe for More Information June 6, 2013 07:08 EDT VSTM Verastem to host business news update conference call Subscribe for More Information 07:02 EDT VSTM Verastem appoints Robert Forrester as CEO Verastem will name Robert Forrester COO and a Director, and Christoph Westphal, M.D., Ph.D., Chairman and CEO, will be transitioning to Executive Chairman. These changes will be effective on July 1. Sign up for a free trial to see the rest of the stories you've been missing.